Journal of Internal Medicine Concepts & Practice››2022,Vol. 17››Issue (04): 353-355.doi:10.16138/j.1673-6087.2022.04.017
• Review article •Previous ArticlesNext Articles
Received:2021-03-08Online:2022-07-18Published:2022-08-08| [1] | Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel[J]. Blood, 2017, 129(4): 424-447. doi:10.1182/blood-2016-08-733196URL |
| [2] | Schuettengruber B, Bourbon HM, Di Croce L, et al. Genome regulation by polycomb and trithorax: 70 years and counting[J]. Cell, 2017, 171(1): 34-57. doi:S0092-8674(17)30890-5pmid:28938122 |
| [3] | Fujino T, Kitamura T.ASXL1mutation in clonal hematopoiesis[J]. Exp Hematol, 2020, 83: 74-84. doi:10.1016/j.exphem.2020.01.002URL |
| [4] | Inoue D, Fujino T, Sheridan P, et al. A novel ASXL1-OGT axis plays roles in H3K4 methylation and tumor suppression in myeloid malignancies[J]. Leukemia, 2018, 32(6): 1327-1337. doi:10.1038/s41375-018-0083-3URL |
| [5] | Scheuermann JC, de Ayala Alonso AG, Oktaba K, et al. Histone H2A deubiquitinase activity of the polycomb repressive complex PR-DUB[J]. Nature, 2010, 465(7295): 243-247. doi:10.1038/nature08966URL |
| [6] | Hsu YC, Chiu YC, Lin CC, et al. The distinct biological implications ofASXL1mutation and its roles in leukemogenesis revealed by a knock-in mouse model[J]. J Hematol Oncol, 2017, 10(1): 1-15. doi:10.1186/s13045-016-0379-6URL |
| [7] | Zhang P, Chen Z, Li R, et al. Loss ofASXL1in the bone marrow niche dysregulates hematopoietic stem and progenitor cell fates[J]. Cell Discov, 2018, 4: 4. doi:10.1038/s41421-017-0004-zpmid:29423272 |
| [8] | 周柰岑, 李国辉, 秦炜炜, 等. 伴ASXL1基因突变的急性髓系白血病患者的临床特征及预后分析[J]. 中国实验血液学杂志, 2021, 29(6):1741-1745. |
| [9] | Kakosaiou K, Panitsas F, Daraki A, et al.ASXL1mutations in AML are associated with specific clinical and cytogenetic characteristics[J]. Leuk Lymphoma, 2018, 59(10): 2439-2446. doi:10.1080/10428194.2018.1433298URL |
| [10] | Kitamura T.ASXL1mutations gain a function[J]. Blood, 2018, 131(3): 274-275. doi:10.1182/blood-2017-12-816595pmid:29348310 |
| [11] | Prats-Martín C, Burillo-Sanz S, Morales-Camacho RM, et al.ASXL1mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype[J]. Cancer Med, 2020, 9(11): 3637-3646. doi:10.1002/cam4.2947URL |
| [12] | 林云. 伴ASXL1基因突变成人初诊急性髓系白血病的临床特征及预后研究[D]. 福建医科大学, 2016. |
| [13] | Alvarez Argote J, Dasanu CA.ASXL1mutations in myeloid neoplasms: pathogenetic considerations, impact on clinical outcomes and survival[J]. Curr Med Res Opin, 2018, 34(5): 757-763. doi:10.1080/03007995.2016.1276896URL |
| [14] | Liu F, Gong M, Gao L, et al. RASSF1A hypermethylation is associated withASXL1mutation and indicates an adverse outcome in non-M3 acute myeloid leukemia[J]. Onco Targets Ther, 2017, 10: 4143-4151. doi:10.2147/OTT.S142528URL |
| [15] | Devillier R, Mansat-De Mas V, Gelsi-Boyer V, et al. Role ofASXL1and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes[J]. Oncotarget, 2015, 6(10): 8388-8396. doi:10.18632/oncotarget.3460pmid:25860933 |
| [16] | 滕广帅, 王颖韶, 徐晶, 等.ASXL1突变的髓系肿瘤患者共突变基因谱及其临床意义[J]. 天津医药, 2018, 46(12): 1295-1299. |
| [17] | Makishima H. SomaticSETBP1mutations in myeloid neoplasms[J]. Int J Hematol, 2017, 105(6): 732-742. doi:10.1007/s12185-017-2241-1pmid:28447248 |
| [18] | 王双玲, 林建雄, 刘峰, 等.TET2在急性髓系白血病中的突变情况及其临床特征[J]. 中国实用医药, 2019, 14(31): 1-3. |
| [19] | Bera R, Chiu MC, Huang YJ, et al.RUNX1mutations promote leukemogenesis of myeloid malignancies inASXL1-mutated leukemia[J]. J Hematol Oncol, 2019, 12(1): 104-122. doi:10.1186/s13045-019-0789-3URL |
| [20] | Nagase R, Inoue D, Pastore A, et al. Expression of mutantASXL1perturbs hematopoiesis and promotes susceptibility to leukemic transformation[J]. J Exp Med, 2018, 215(6): 1729-1747. doi:10.1084/jem.20171151URL |
| [21] | Carbuccia N, Trouplin V, Gelsi-Boyer V, et al. Mutual exclusion ofASXL1andNPM1mutations in a series of acute myeloid leukemias[J]. Leukemia, 2010, 24(2): 469-473. doi:10.1038/leu.2009.218pmid:19865112 |
| [22] | 胡晋君.TET2(rs2454206、rs12498609)及ASXL1(rs3746609) 单核苷酸多态性与MDS及其向AML转化的相关性研究[D]. 山西医科大学,2019. |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||
